Infectious Diseases Pharmacotherapy Research Articles

Let's Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?

It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses. The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0-10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables. SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4-9), 5 (3-8), and 8 (4-10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317-.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758-.870), 0.745 (95% CI, .656-.816), and 0.833 (95% CI, .775-.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful. Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.

How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists.

Clinicians, researchers, and the public frequently turn to digital channels and social media for up-to-the-minute information on novel therapeutics and vaccines. The value of credible infectious diseases drug information is more apparent in the setting of the coronavirus disease 2019 (COVID-19) pandemic. This viewpoint by the Society of Infectious Diseases Pharmacists (SIDP) provides guidance on utilizing social media platforms to optimize infectious diseases pharmacotherapy. It includes tips for all levels of users but primarily serves a guide for the infectious diseases clinician who has not yet joined social media. It compares various social media platforms and suggests which to begin with based on user needs, recommends efficient curation of social media content, and outlines a stepwise approach (shown below) to increasing engagement over time. This summary will hopefully spur further quality content and engagement regarding drug information from the infectious diseases social media network.

Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.

BackgroundStarting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), bamlanivimab and etesivimab, casirivimab and imdevimab (REGEN-COV), and sotrovimab, for treatment or postexposure prophylaxis of Coronavirus disease 2019 (COVID-19) in adolescents (≥12 years of age) and adults with certain high-risk conditions. Previous guidance is now updated based on new evidence and clinical experience.MethodsA panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacotherapy, and pediatric critical care medicine from 18 geographically diverse US institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on a review of the best available evidence and expert opinion.ResultsThe course of COVID-19 in children and adolescents is typically mild, though more severe disease is occasionally observed. Evidence supporting risk stratification is incomplete. Randomized controlled trials have demonstrated the benefit of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific monoclonal antibody therapies in adults, but data on safety and efficacy in children or adolescents are limited. Potential harms associated with infusion reactions or anaphylaxis are reportedly low in adults.ConclusionsBased on evidence available as of August 31, 2021, the panel suggests a risk-based approach to administration of SARS-CoV-2 monoclonal antibody therapy. Therapy is suggested for the treatment of mild to moderate COVID-19 in adolescents (≥12 years of age) at the highest risk of progression to hospitalization or severe disease. Therapeutic decision-making about those at moderate risk of severe disease should be individualized. Use as postexposure prophylaxis could be considered for those at the highest risk who have a high-risk exposure but are not yet diagnosed with COVID-19. Clinicians and health systems should ensure safe and timely implementation of these therapeutics that does not exacerbate existing healthcare disparities.

A national standard that will influence global efforts to protect antibiotics

Though the infectious diseases (ID) pharmacy specialty has been in existence for many years, recent issues have raised the profile of ID pharmacists within the healthcare system. First, antimicrobial resistance rates have reached a crisis point and gained the attention of international organisations.1 Second, and in large part due to antimicrobial resistance, recognition of the suboptimal use of antimicrobial agents has led to the rapid expansion of antimicrobial stewardship programs (ASPs) in many parts of the world.2-4 Finally, the COVID-19 pandemic has highlighted the importance of leadership that understands that practical aspects of antimicrobial pharmacotherapy can rapidly synthesise emerging literature and gain consensus through collaboration to produce local standards. All of these require expertise in antimicrobial therapies, and consequently the need for ID pharmacists has grown. The SHPA Standard of Practice (SOP) in Infectious Diseases for Pharmacy Services sets important national expectations and guidance for pharmacist practitioners wishing to practice ID. We believe that this document espouses the mission of the Society of Infectious Diseases Pharmacists (SIDP), which is to advance infectious diseases pharmacotherapy and lead antimicrobial stewardship to optimise the care of patients with infections. Both of us have served as President of SIDP and we see parallels between this SOP and the mission of SIDP. The SOP highlights the important contributions (in both depth and breadth) to direct patient care by ID pharmacists in varied practice settings including inpatient hospital care, people living with HIV, antimicrobial stewardship, rural and regional health services, community-based parenteral antibiotic therapy and emerging practices in primary care and aged care facilities. The standard also emphasises essential components of ID pharmacy practice beyond front-line patient care and operations: education quality and safety improvement, policy and protocol development, and research. This includes the importance of regional, national, and international collaborations to advance the science and to act as a mechanism that shares knowledge and best practices. The latter is especially pertinent for pharmacists practicing in settings without the benefit of colleagues in the specialty, including ID physicians. Perhaps more important is that this SOP also sets a standard for ID practice to include pharmacist practitioners in key clinical and administrative roles. The latter is not a standalone section but rather woven into all aspects of ID pharmacy practice. The standard also highlights the collaborative nature of infectious diseases practice and specifically mentions the important role of microbiology and infection prevention working together with the ID team to achieve optimal patient care. Highlighting the role of ID pharmacists in hospital leadership throughout the antimicrobial use process is key. Although written for Australia, this SOP has the potential for international impact. Pharmacy practice in other countries may come to mirror best practices described in documents such as this one. At the invitation of the authors, the two of us reviewed and provided input on a draft of this standard with this in mind. They are congruent with positions on pharmacist roles in the leadership of ASPs taken by the Board of Pharmacy Specialties and by SIDP.5-7 The SOP takes a big step forward and sets a standard that acts as a set of goals for pharmacists practicing in ID. These goals will likely change as practices evolve and ID pharmacists find new and innovative ways to improve the care of patients. With these standards as the starting point, ID pharmacists can further the vision of ensuring safe and effective antibiotics for now and the future. The authors have no conflicts of interests to declare.

Clinical Utility of Lefamulin: If Not Now, When?

Purpose of ReviewThe looming threat of antimicrobial resistance requires robust stewardship and new developments in infectious diseases pharmacotherapy. This review discusses the pertinent spectrum and clinical data of lefamulin (Xenleta®), with a focus on potential real-world use.Recent FindingsLefamulin is a novel pleuromutilin antibiotic that obtained Food and Drug Administration labeling for community-acquired bacterial pneumonia (CABP) in 2019. Lefamulin is available in both intravenous and oral formulations, and it inhibits bacterial protein synthesis inhibition through interactive binding to unique sites of the peptidyl transferase center of the 50s bacterial ribosome subunit. Resistance, including cross-resistance with other antibiotics, is infrequent. Lefamulin demonstrates activity against most Gram-positive pathogens and other organisms commonly associated with CABP, i.e., Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydophila pneumoniae. Lefamulin may also be an option for serious public health threats like methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and multi-drug-resistant organisms associated with sexually transmitted infections, e.g., Neisseria gonorrhoeae, Mycoplasma genitalium. Lefamulin lacks activity against Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacterales, most anaerobes, and E. faecalis. In Phase III trials, lefamulin monotherapy was non-inferior to moxifloxacin with or without linezolid for CABP.SummaryLefamulin is a well-tolerated agent with a unique mechanism, availability in both IV and PO formulations, and it has been rigorously studied for safety and efficacy for CABP.

Self-perceived knowledge and confidence regarding infectious diseases of advanced pharmacy practice experience students

IntroductionKnowledge in infectious diseases (ID) pharmacotherapy and antimicrobial stewardship is becoming increasingly important for pharmacists. Pharmacy schools utilize multiple methods to teach ID pharmacotherapy including advanced pharmacy practice experiences (APPEs). MethodsAn internet-based survey was sent to students currently on APPEs at four colleges/schools of pharmacy. The primary study objective was a comparison of self-perceived ID knowledge and confidence prior to starting and during APPEs. The secondary objectives were to determine the level of self-perceived knowledge and confidence of students who have completed an ID APPE to those who have not, as well as the level of interest in postgraduate year 1 (PGY-1) and ID-specific postgraduate year 2 (PGY-2) residencies. ResultsAll statements revealed a statistically significant increase in self-perceived ID knowledge and confidence for students during APPEs compared to before starting rotations (p-values < 0.001). Students who completed an ID APPE had an overall increase in both self-perceived knowledge and confidence for all aspects. Completion of an ID APPE enhanced self-perceived knowledge in basic microbiology fundamentals, antimicrobial stewardship principles, and overall ID knowledge. Completion of an ID APPE created a higher level of confidence regarding selecting appropriate antimicrobial therapy, interpreting cultures and susceptibilities to de-escalate, and communicating with other healthcare professionals. ConclusionsStudents who completed an ID APPE had a higher level of self-perceived knowledge and confidence than those who had not. Recent increases in demand for antimicrobial stewardship positions warrants maximization of ID and non-ID APPEs to enhance students' knowledge and confidence in infectious diseases.

981. A Comprehensive Survey of Infectious Diseases Curriculum Among US Pharmacy Schools

BackgroundPharmacists are key partners in institutional antimicrobial stewardship and require adequate knowledge and skills in antimicrobial pharmacotherapy to fulfill this role, whether or not they have specialized postgraduate training in infectious diseases (ID). The objective of this study was to describe ID topics and teaching strategies across US schools of pharmacy.MethodsA 23-question electronic survey was sent to ID faculty or curricular deans at all 137 US pharmacy schools.ResultsSurveys were collected from 106 schools (77% response rate). ID curriculum was allotted 60 (IQR 40–80) hours of classroom time and primarily taught in the third year. Respondents dedicated 33% of curriculum hours to ID fundamentals and 66% to disease states. Content was primarily delivered through traditional lectures compared with active learning (75% and 25%, respectively). Greater than 94% of schools taught all tier 1 ID topics from the 2016 American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. Utilization of active learning methods and time allocated to ID fundamentals differed across schools. Public schools dedicated more time to antimicrobial fundamentals than private schools (40 vs. 30 hours, P = 0.023). Schools using a block schedule allotted more classroom hours to ID content than schools using semester or quarter schedules (77.5 vs. 60 vs. 50 hours, P = 0.001). Schools established less than 5 years ago devoted more classroom hours to active learning than schools established 5 to 10, 11 to 20, and greater than 20 years ago (65 vs. 25 vs. 25 vs. 20, P = 0.012). Private schools were more likely to consistently or frequently use audience response systems (86% vs. 68%, P = 0.037) and concept maps (27% vs. 6%, P = 0.005) compared with public schools. Public schools were more likely to use debates (18% vs. 2%, P = 0.006). Schools established 10 or less years ago were more likely to use concept maps (28% vs. 12%, P = 0.050), games (38% vs. 19%, P = 0.050), and simulation (41% vs. 18%, P = 0.015).ConclusionIncreased communication and collaboration between ID pharmacotherapy educators is warranted to increase consistency of ID education and distribution of educational innovations.Disclosures All authors: No reported disclosures.

Preventing the Post-Antibiotic Era by Training Future Pharmacists as Antimicrobial Stewards

Antimicrobials enable modern medicine, but their efficacy is a limited resource. In the past 20 years, antimicrobial development has slowed dramatically while antimicrobial resistance continues to rise. In response to this, there has been an increased focus on strategically managing antimicrobial use with an approach called "antimicrobial stewardship." Antimicrobial stewardship programs have been endorsed by health systems, professional societies, regulators, and government. These programs have been shown to reduce antimicrobial use, slow the growth of antimicrobial resistance, and improve patient outcomes. This commentary will discuss recent mandates for antimicrobial stewardship, compare current approaches to teaching infectious diseases pharmacotherapy with the skills and knowledge required for antimicrobial stewardship, and provide recommendations for and examples of best practices in training student pharmacists to become antimicrobial stewards.

Impact of an infectious diseases advanced pharmacy practice experience on student knowledge

IntroductionThe goal of this assessment was to determine knowledge acquisition by pharmacy students during an infectious diseases (ID) advanced pharmacy practice experience (APPE). MethodsA 50-question knowledge-based examination was given to every student on a five-week ID APPE between July 1, 2013 and May 5, 2017. The examination was also given to control students (those who did not have an ID APPE) immediately prior to graduation. The primary outcome was difference in examination performance after completion of the ID APPE. Secondary outcomes included correlations between examination performance and number of previous inpatient clinical rotations (ICR), average score in therapeutic coursework (TC), and rotation block (RB). ResultsForty students were included (control = 5, experimental = 35). Average pre-test scores were similar between experimental and control students [61.7 (10.9)% versus 62.0 (5.1)%, respectively], but experimental post-test scores [80.2 (7.9)%] were significantly better than pre-test scores for both experimental (p < .05) and control student (p < .05) examination scores. ICR [1.3 (1.0) rotations], TC [81.5 (3.9)%], and RB (median = 4) had a positive correlation with pre-examination performance (R = .5, .5, and .4, respectively). DiscussionImproved ID pharmacotherapy knowledge is needed. Baseline scores of students taking an ID elective were similar to control students who completed the entire year of APPEs, and knowledge scores were higher in ID students after APPE completion. There was a positive, but not strong, correlation between pre-examination performance and number of previous rotations, therapeutic coursework, and rotation block. ConclusionA five-week ID elective APPE improved student performance on a knowledge-based examination. Consideration should be given to more consistent integration of ID principles across all rotation types.

Significant publications on infectious diseases pharmacotherapy in 2015.

The most important articles on infectious diseases (ID) pharmacotherapy published in the peer-reviewed literature in 2015, as nominated and selected by panels of pharmacists and others with ID expertise, are summarized. Members of the Houston Infectious Diseases Network were asked to nominate articles published in prominent peer-reviewed journals in 2015 that were thought to have a major impact in the field of ID pharmacotherapy. A list of 55 nominated articles on general ID-related topics and 10 articles specifically related to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) was compiled. In a national online survey, members of the Society of Infectious Diseases Pharmacists (SIDP) were asked to select from the list 10 general ID articles believed to have made a significant contribution to the field of ID pharmacotherapy and 1 article contributing to HIV/AIDS pharmacotherapy. Of the 361 SIDP members surveyed, 153 (42%) and 76 (21%) participated in the selection of general ID-related articles and HIV/AIDS-related articles, respectively. The 11 highest-ranked publications (10 general ID-related articles and 1 HIV/AIDS-related article) are summarized here. With the growing number of significant ID-related publications each year, it can be challenging to stay current with the literature. This review of important ID pharmacotherapy publications in 2015 may be helpful in identifying key articles and lessening this burden.

Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis

Cystic fibrosis (CF) affects several organs, most notably the lungs, which become predisposed to infections with potentially severe consequences. Because of physiologic changes and infection characteristics, unique approaches to antimicrobial agent selection, dosing, and administration are needed. To provide optimal acute and long-term care, pediatric health care providers must be aware of these patient features and common approaches to antimicrobial therapy in CF, which can differ significantly from those of other infectious diseases. The purpose of this article is to review common respiratory pathogens, pharmacology of commonly used antimicrobial agents, and unique pharmacokinetics and dosing strategies often used when treating children with CF.

Significant publications on infectious diseases pharmacotherapy in 2014.

The most important articles on infectious diseases (ID) pharmacotherapy published in the peer-reviewed literature in 2014, as nominated and selected by panels of pharmacists and others with ID expertise, are summarized. Members of the Houston Infectious Diseases Network were asked to nominate articles published in 2014 from prominent peer-reviewed journals that were felt to have a major impact in the field of ID pharmacotherapy. A list of 19 nominated articles on general ID-related topics and 9 articles specifically related to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) was compiled. In a national online survey, members of the Society of Infectious Diseases Pharmacists (SIDP) were asked to select from the list 10 general ID articles believed to have made a significant contribution to the field of ID pharmacotherapy and 1 article contributing to HIV/AIDS pharmacotherapy. Of the 291 SIDP members surveyed, 134 (46%) and 56 (19%) participated in the selection of general ID-related articles and HIV/AIDS-related articles, respectively. The 11 highest-ranked papers (10 general ID-related articles, 1 HIV/AIDS-related article) are summarized here. With the vast number of articles published each year, it is difficult to remain up-to-date on current, significant ID pharmacotherapy publications. This review of significant publications in 2014 may be helpful by lessening this burden.

Significant publications on infectious diseases pharmacotherapy in 2013.

The most important articles on infectious diseases (ID) pharmacotherapy published in the peer-reviewed literature in 2013, as nominated and selected by panels of pharmacists and others with ID expertise, are summarized. Members of the Houston Infectious Diseases Network were asked to nominate articles published last year in prominent biomedical journals that had a major impact in the field of ID pharmacotherapy. A list of 27 nominated articles on ID-related topics in general and 26 articles specifically focused on human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) was compiled. In a national online survey conducted in January 2014, members of the Society of Infectious Diseases Pharmacists (SIDP) were asked to select from the list those articles that they felt had made the greatest contributions to the field of ID pharmacotherapy. Of 168 SIDP members surveyed, 108 (64%) and 53 (32%) participated in the selection of ID- and HIV/AIDS-related articles, respectively. Summaries of the top-ranked articles in both categories are presented. Major topics explored in the top-ranked ID articles of 2013 include the use of cefepime for gram-negative infections due to AmpC or extended-spectrum β-lactamase-producing Enterobacteriaceae, optimizing antibiotic therapy through the use of extended- or continuous-infusion regimens, the use of the oral integrase inhibitor dolutegravir to combat HIV disease, and new approaches to treatment of Clostridium difficile infection and enterococcal endocarditis.

Significant publications on infectious diseases pharmacotherapy in 2012

The most important articles pertaining to infectious diseases (ID) pharmacotherapy published in 2012, as nominated and ranked by panels of pharmacists and physicians with ID expertise, are summarized. Members of the Houston Infectious Diseases Network were asked to nominate articles on ID research published in prominent peer-reviewed journals during the period January 1-December 31, 2012, with a major impact in the field of ID pharmacotherapy. A list of 42 nominated articles on general ID-related topics and 8 articles pertaining to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) was compiled. In a survey conducted in January 2013, members of the Society of Infectious Diseases Pharmacists (SIDP) were asked to select from the list 10 general ID articles and 1 HIV/AIDS-related article that they considered to be the most important. Of the 180 SIDP members surveyed, 100 (55%) and 44 (24%) participated in ranking the general ID and HIV/AIDS-related articles, respectively. Summaries of the highest-ranked articles in both categories are presented here. With the volume of published ID-related research growing each year, both ID specialists and nonspecialists are challenged to stay current with the literature. Key ID-related publications in 2012 included updated recommendations on management of diabetic foot infections, articles on promising approaches to prevention and early treatment of HIV disease, and reports on developments in research on pharmacotherapies for methicillin-resistant Staphylococcus aureus bacteremia and Klebsiella pneumoniae infections.

Adherence to the 2009 Consensus Guidelines for Vancomycin Dosing and Monitoring Practices: A Cross-Sectional Survey of U.S. Hospitals

To describe the implementation of vancomycin dosing and monitoring practices recommended by the consensus guidelines in a diverse sample of hospitals, and to identify needs for quality improvement and research. Cross-sectional study using an online survey instrument. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Research Network. A total of 163 respondents from MAD-ID who work in antimicrobial stewardship and represent unique hospitals. The survey population represented a wide range of patient populations (96% adult, 49% pediatric, and 23% long-term care) and settings (52% not-for-profit nonuniversity, 31% university based, and 11% for profit). Automatic consultation of pharmacy services for all vancomycin dosing was reported in 51% of the institutions. Among the dosing and monitoring practices endorsed by the consensus guidelines, participant institutions commonly followed these recommendations: use of trough concentrations without peak concentrations, maintenance of trough concentration higher than 10mg/L, and target trough concentrations of 15-20mg/L for complicated infections. In contrast, there was less consistent application of appropriate timing of trough concentrations, use of loading doses, and use of actual body weight. The remaining challenges and controversies surrounding vancomycin dosing are discussed. Despite the availability of consensus guideline recommendations, practices for dosing and monitoring of vancomycin are not universally applied. The findings of this survey highlight many opportunities for future research and quality improvement strategies.

Significant publications on infectious diseases pharmacotherapy in 2011

Important articles on topics pertinent to infectious diseases (ID) pharmacotherapy published in prominent peer-reviewed journals in 2011 are summarized. Pharmacists, physicians, and researchers from the Houston Infectious Diseases Network were asked to nominate articles published in 2011 that they perceived as having a significant impact on the field of ID pharmacotherapy. The resulting list, comprising 10 articles related to human immunodeficiency virus (HIV) disease or acquired immune deficiency syndrome (AIDS) and 38 articles on a broad range of other ID-related topics, was sent to members of the Society of Infectious Diseases Pharmacists (SIDP) for evaluation via an Internet survey. The survey participants were asked to select 10 articles from the list of general ID articles and 1 article from the HIV- or AIDS-related articles that they viewed as having the most impact on the field. Of the 328 SIDP members surveyed, 120 (37%) ranked the non-HIV-related papers and 55 (17%) ranked the HIV-related papers. The 12 highest-ranked items-including 3 guidelines-are summarized here. Due to the increasing number of articles published each year, it is difficult to maintain a current knowledge of significant publications in the field of ID pharmacotherapy. This review of the key articles in 2011 may be helpful to the nonspecialist clinician by lessening this burden.

Significant publications on infectious diseases pharmacotherapy in 2010

Important articles on topics pertinent to infectious diseases (ID) pharmacotherapy published in prominent peer-reviewed journals in 2010 are summarized. At the end of 2010, pharmacists, physicians, and researchers in the Houston Infectious Diseases Network were asked to nominate articles published from January through December 2010 that they perceived as having a significant impact in the field of ID pharmacotherapy. The resulting list, comprising 27 articles relating to human immunodeficiency virus (HIV) disease or acquired immune deficiency syndrome (AIDS) and 52 articles on a broad range of other ID-related topics, was sent to members of the Society of Infectious Diseases Pharmacists (SIDP) for evaluation via an Internet survey. The survey participants were asked to select from the list 10 articles unrelated to HIV or AIDS and 1 HIV- or AIDS-related article that in their view had the most significant impact in the field. Of the 380 SIDP members surveyed, 105 (27.6%) ranked the non-HIV-related papers and 45 (11.8%) ranked the HIV-related papers. The 11 highest-ranked publications-including 2 articles presenting updated practice guidelines-are summarized here. Due to the increasing number of articles published each year, it is difficult to maintain a current knowledge of significant publications in the field of ID pharmacotherapy. This review of key publications in 2010 may be helpful to the nonspecialist clinician by lessening this burden.

Significant publications on infectious diseases pharmacotherapy in 2009

Significant publications on infectious diseases (ID) pharmacotherapy in 2009 are summarized. On December 31, 2009, the Houston Infectious Diseases Network amassed a list of articles identified as having a significant impact on ID pharmacotherapy. Articles selected were published between January 1, 2009, and December 31, 2009, in prominent, peer-reviewed journals. Articles were selected based on their perceived potential impact on pharmacy practice in ID, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS). A list of 45 articles not related to HIV infection and 17 articles related to HIV infection was distributed to members of the Society of Infectious Diseases Pharmacists (SIDP) via an Internet survey. Members were asked to select the 10 publications (from the list of 45 non-HIV-related articles) that they felt contributed most to ID pharmacotherapy and to select the single most significant publication from the list of 17 articles related to HIV or AIDS. Of the 531 SIDP members surveyed, 100 responded (18.8%). The top 10 articles (9 non-HIV-related and 1 HIV-related) identified from this survey are summarized in this article. Three of the top 10 articles selected from the non-HIV category included new or updated ID guidelines. Summaries of the top articles selected (9 non-HIV-related and 1 HIV-related) from this survey are included. Due to the growing number of articles published each year, it is difficult to maintain a current knowledge of significant publications in ID. This review of significant publications in ID pharmacotherapy can be helpful by lessening this burden.

Significant publications on infectious diseases pharmacotherapy in 2008

Significant publications on infectious diseases (ID) pharmacotherapy in 2008 were compiled and summarized. On December 31, 2008, the Houston Infectious Diseases Network compiled a listing of published articles identified as having a significant impact on ID pharmacotherapy. The publication period was limited to January 1 through December 31, 2008. Articles were selected based on prior presentations at ID and pharmacy meetings or were listed as major articles in prominent ID journals. Priority was given to articles that were published in peer-reviewed journals and to treatment guidelines endorsed by major medical and pharmacy organizations. A bibliography of 56 articles (40 not related to human immunodeficiency virus [HIV] infection and 16 related to HIV infection) was distributed to members of the Society of Infectious Diseases Pharmacists (SIDP) via an Internet survey in early January 2009. Members were asked to select 10 publications not related to HIV infection and 1 HIV-related publication that they believed made the greatest contribution to the antimicrobial-related medical literature in 2008. A total of 115 SIDP members participated in the survey. Summaries of the top articles selected, along with an interpretation of their effect on clinical practice, are included. The increasing number of articles in the peer-reviewed medical literature related to the diagnosis and treatment of ID has made it challenging to maintain a contemporary knowledge base of key publications. This summary of significant ID articles published in 2008 can help to alleviate this burden.

Recommendations for Training and Certification for Pharmacists Practicing, Mentoring, and Educating in Infectious Diseases Pharmacotherapy

Recently created guidelines for the development of institutional antimicrobial stewardship programs recommend that a pharmacist with infectious diseases training be included as a core member of the antimicrobial stewardship team. However, training and certification requirements for infectious diseases-trained clinical pharmacists have not been established. Although pharmacists have nurtured their interest in infectious diseases by self-directed learning or on-the-job experiences, this mode of training is not considered feasible or sufficient for reliable training of future clinical specialists in infectious diseases. This document, therefore, is forward looking and provides overarching recommendations for future training and certification of pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy, with the recognition that full implementation may take several years. We recommend that future pharmacists wishing to obtain a clinical position as an infectious diseases-trained pharmacist should complete a postgraduate year (PGY) 1 residency and a PGY2 residency in infectious diseases, that practitioners become board-certified pharmacotherapy specialists, that a certification examination in infectious diseases be developed, that practitioners maintain a portfolio of educational experiences to maintain qualifications, that current nonaccredited training programs seek accreditation, and that employers and academicians recognize the desirability of these qualifications in hiring decisions.